TETRA BIO-PHARMA WKN: A2ASQ8 ISIN: CA88166Y1007 Kürzel: TBP Forum: Aktien Thema: Hauptdiskussion

Gibt es die Bude doch noch?

Sieht schlecht aus… Tetra Bio-Pharma makes voluntary bankruptcy assignment 2023-08-01 11:45 ET - News Release An anonymous director reports TETRA BIO-PHARMA VOLUNTARY BANKRUPTCY Tetra Bio-Pharma Inc. has made a voluntary assignment into bankruptcy under the Bankruptcy and Insolvency Act (Canada). Houle Roy SA has been appointed as Tetra's trustee in bankruptcy. On March 7, 2023, the corporation announced that the Ontario Securities Commission rejected an application for a management cease trade order (MCTO). The rejected MCTO prevented the corporation from negotiating any securities to continue to finance the corporation and blocked Tetra from paying debt with shares. Based on these events, the corporation had no other choice but to make a voluntary assignment into bankruptcy.

MONTREAL, QUEBEC – TheNewswire – March 1, 2023 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTC-PINK: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, announced today that it will not be in a position to file its audited annual financial statements for the year ended November 30, 2022, the related management's discussion and analysis and related CEO and CFO certificates before the required deadline of February 28, 2023. The Company also announced PwC (PricewaterhouseCoopers LLP) has resigned as auditors and are now working with McGovern Hurley LLP to complete the preparation of these filings and expects to file its 2022 annual financial statements and related management's discussion and analysis on or before April 15, 2023. The Company has applied to the Ontario Securities Commission, as principal regulator for the Company, for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203") throughout the duration of the default. The management cease trade order, if approved, will generally not affect the ability of persons who are not or have not been management of the Company to trade in its securities. The Company confirms that it will satisfy the provisions of the alternative information guidelines under NP 12-203 by issuing biweekly default status reports in the form of news releases for so long as it remains in default of the above-noted filing requirements. The Company confirms other than its financial results for the year ended November 30, 2022, there is no other material information relating to its affairs that has not been generally disclosed. Other than as disclosed herein, the Company is up to date in its filing obligations.

OTCPink… habe ich noch nie gehört

MONTREAL, Feb. 10, 2023 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTC-PINK: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, today announced that its common shares began trading on the OTC Markets Group's OTCPink Market in the United States under the symbol "TBPMF" effective at the opening of trading on Friday, February 10, 2023 and will continue to trade on the Toronto Stock Exchange (the "TSX") under the ticker symbol "TBP". Existing U.S. shareholders of Tetra will now find common shares quoted on the OTCPink without any further action needed. The Pink Open Market provides brokers with a regulated platform for transparent trading and best execution. Brokers quote a wide **** of companies on this market, including foreign companies that limit their disclosure in the U.S., penny stocks and shells. To be eligible for quotation on the Pink Market, companies must comply with the requirements of Securities Exchange Act Rule 15c2-11, including providing current information to the investing public

Tetra Bio-Pharma Inc. has provided its shareholders with another regulatory update on the Reduvo new drug submission (NDS). The last update was provided on November 18, 2022. On December 21, 2022, the Company received a second Clarification Request (Clarifax) from Health Canada regarding the product's Risk Management Plan, which is not atypical for a controlled substance drug. The Company will be submitting the response to Health Canada within the allowed timeframe. The Company cannot comment on Health Canada's response timelines. Questions/feedback from Health Canada are received as the review of the dossier progresses through different review streams.

Ist das Ding tot hier

https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2022/Tetra-Bio-Pharma-Provides-Update-on-Patent-Applications-for-Novel-Therapeutic-ARDS-003/default.aspx

Hoffen und beten leute. Das kann es sein..!

https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2022/Tetra-Bio-Pharma-Provides-Update-on-Its-REDUVO-New-Drug-Submission/default.aspx?fbclid=IwAR3weOn1_zfYwrnEjpo-ZGCCiJBEXG2uCfl6JbGc8yXmiHxSqaCSZSnNGss&mibextid=Zxz2cZ

Langsam bleibt nichts mehr übrig 🙈

Tetra Bio-Pharma Inc. has signed an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product, with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug.

Zumindest neue Finanzmittel OTTAWA, ON, Aug. 11, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, announced today that it has entered into a subscription agreement (the "Subscription Agreement") with Global Corporate Finance Opportunities 16 (the "Investor"), an investment vehicle advised by Alpha Blue Ocean Inc. ("ABO"), whereby Tetra has agreed to issue to the Investor (i) senior unsecured convertible debentures ("Debentures") in the aggregate principal amount of up to $6,000,000, and (ii) warrants ("Warrants") to purchase common shares ("Common Shares") in the capital of the Company (collectively, the "Offering").

Mit mäßigem Erfolg 🙈

Cannabis-derived drug developer, Tetra Bio-Pharma Inc. (TBP), shared positive preclinical results from live COVID-19 infection studies and a septic lung model. The company stated these independently researched studies observed ARDS-003 and its potential to increase survival rates following a COVID-19 infection in a “humanized” mouse model. According to the company, ARDS-003 is a new drug which contains, a potent substance from a type two cannabinoid receptor, onternabez, which is an important immune system target. Tetra stated ARDS-003 can help regulate acute systemic inflammation and prevent sepsis, lung dysfunction, and organ damage. Allegedly, the studies demonstrated that ARDS-003 decreases hyperinflammatory response and slows disease progression. On top of this, Tetra shared that when using a recent septic lung model ARDS-003 produced a significant reduction of systemic cytokine and chemokine release. Lung tissue was improved, peripheral immune hyperactivation was reduced, and there was an improvement in capillary perfusion in lung tissue compared to controls. The company’s research team has also developed an oral formulation of the drug for an immediate release that can be used over time and may work well alongside other treatements.